Clinical Trial

Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

Recruiting
View on ClinicalTrials.gov →
Summary
CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-09-08; most recent amendment 2026-03-17.
Status change: Active, Not Recruiting → Recruiting 2022-07-20
Trial Details
NCT Number NCT04546945
Lead Sponsor Asmaa Hassan mohamed Abdel Mawjoud
Conditions Hematologic Malignancies
Enrollment 38 participants
Start Date 2027-03-20
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-18